September 03, 2009
« Back to news listIcosagen Cell Factory granted a license to Bayer HealthCare
Icosagen Cell Factory OÜ and Bayer HealthCare extended an existing agreement, pursuant to which a non-exclusive licence to use QMCF technology for research activities was granted to Bayer HealthCare.About QMCF Technology
QMCF technology is a new conceptual method of combining several biological elements to produce proteins for early stage drug development processes. The technology provides an advantage, compared to existing technologies, in crucial aspects, such as timeline, stability and cost-effectiveness. In addition, it is applicable to development test-systems for drug target screening, large scale protein production, etc. QMCF Technology was developed by Icosagen Cell Factory OÜ during the period 2005-2008. The development of the technology was financed by Enterprise Estonia. The technology has been granted a European Patent. Patent applications have been filed in the US, Canada, Australia and Japan.
About Icosagen Cell Factory
Icosagen Cell Factory OÜ was established in 2005. The company is dedicated to the development of the portfolio of QMCF technology-based applications. The company belongs to Icosagen Group.
Contact Information:
Marit Jaaska, Business Development Manager
E-mail: marit.jaaska[at]quattromed.com
